J Stroke > Volume 26(2); 2024 > Article |
|
Characteristic | Entire patient sample (n=1,099) | Patients with 90-day mRS 0-2 (n=665) | Patients with 90-day mRS >2 (n=434) | P |
---|---|---|---|---|
Baseline characteristics | ||||
Age (yr) | 70.8 (60.7-79.8), n=1,099 | 66.7 (58.4-75.9), n=665 | 76.6 (66.9-83.3), n=434 | <0.001 |
Female sex | 546/1,099 (49.7) | 312/665 (46.9) | 234/434 (53.9) | 0.026 |
Baseline NIHSS | 17 (12-21), n=1,099 | 16 (11-20), n=665 | 18 (15-22), n=434 | <0.001 |
Baseline ASPECTS | 8 (7-9), n=1,099 | 8 (7-9), n=665 | 8 (7-9), n=434 | 0.024 |
ASPECTS | 0.068 | |||
0-6 | 192/1,099 (17.5) | 102/665 (15.3) | 90/434 (20.7) | |
7-8 | 587/1,099 (53.4) | 362/665 (54.4) | 225/434 (51.8) | |
9-10 | 320/1,099 (29.1) | 201/665 (30.2) | 119/434 (27.4) | |
Collaterals | <0.001 | |||
Poor | 46/1,087 (4.2) | 15/658 (2.3) | 31/429 (7.2) | |
Intermediate | 851/1,087 (78.3) | 524/658 (79.6) | 327/429 (76.2) | |
Good | 190/1,087 (17.5) | 119/658 (18.1) | 71/429 (16.6) | |
Treatment, procedural outcomes, and workflow times | ||||
Successful reperfusion (eTICI 2b-3) | 954/1,093 (87.3) | 618/661 (93.5) | 336/432 (77.8) | <0.001 |
Near-complete reperfusion (eTICI 2c-3) | 505/1,093 (46.2) | 349/661 (52.8) | 156/432 (36.1) | <0.001 |
Time from onset to randomization (min) | 187 (121-309), n=1,099 | 170 (114-275), n=665 | 217 (135-350), n=434 | <0.001 |
Time from study drug to reperfusion (min) | 22 (8-41), n=966 | 21 (8-37), n=627 | 26 (9-52), n=339 | 0.001 |
Time from qualifying CT to groin puncture (min) | 45 (30-65), n=1,096 | 44 (30-62), n=663 | 48 (31-70), n=433 | 0.059 |
General anesthesia | 190/1,093 (17.4) | 86/662 (13.0) | 104/421 (24.1) | <0.001 |
Intravenous alteplase | 656/1,099 (59.7) | 423/665 (63.6) | 233/434 (53.7) | 0.001 |
Intravenous nerinetide | 547/1,099 (49.8) | 336/665 (50.5) | 211/434 (48.6) | 0.538 |
Quantitative tissue imaging variables | ||||
Total infarct volume (mL) | 24.9 (6.6-92.2), n=1,099 | 13.0 (3.9-36.3), n=665 | 87.1 (26.8-203.2), n=434 | <0.001 |
Grey matter infarct volume (mL)* | 18.8 (8.5-37.3), n=358 | 13.6 (6.3-26.9), n=245 | 35.2 (17.9-60.9), n=113 | <0.001 |
White matter infarct volume (mL)* | 0 (0-8.3), n=358 | 0 (0-1.4), n=245 | 8.1 (0-52.6), n=113 | <0.001 |
Superficial grey matter infarct volume (mL)* | 6.3 (0-29.3), n=358 | 2.0 (0-17.5), n=245 | 25.3 (6.1-51.9), n=113 | <0.001 |
Deep grey matter infarct volume (mL)* | 7.0 (2.1-13.5), n=358 | 6.5 (2.1-12.9), n=245 | 8.8 (2.1-15.7), n=113 | 0.205 |
Parenchymal hemorrhage | 351/1,099 (31.9) | 197/665 (29.6) | 197/434 (45.4) | <0.001 |
Parenchymal hemorrhage volume (mL)† | 0 (0-1.1), n=1,054 | 0 (0-0), n=648 | 0 (0-8.9), n=406 | <0.001 |
Clinical outcomes | ||||
mRS 0-2 at 90 days | 665/1,099 (60.5) | - | - | - |
Mortality at 90 days | 142/1,099 (12.9) | - | 142/434 (32.7) | - |
Ordinal mRS at 90 days | 2 (1-4), n=1,099 | 1 (0-2), n=665 | 5 (3-6), n=434 | - |
Symptomatic intracranial hemorrhage | 31/1,096 (2.8) | 4/664 (0.6) | 27/432 (6.3) | <0.001 |
Thrombectomy in Acute Ischemic Stroke: Challenges to Procedural Success2017 May;19(2)